Association between bullous pemphigoid and psoriasis: A case-control study To the Editor: Although the coexistence of bullous pemphigoid (BP) and psoriasis has been described, the association between the two entities is still to be established. 1 The prevalence rate of psoriasis among patients with BP is inconsistent in different BP cohorts. 2, 3 Little is known about differences in demographics, clinical presentation, immunopathologic features, management, and prognosis between patients with isolated BP and those with coexisting BP and psoriasis.
We sought to compare the prevalence of psoriasis in an immunopathologically validated large cohort of BP patients relative to age-, sex-, and ethnicitymatched control subjects. Our second endpoint was to characterize the subgroup of patients with concomitant BP and psoriasis relative to patients with BP without psoriasis.
The study was designed as a case-control study. The case group comprised all consecutive patients with a new diagnosis of BP between January 2000 and December 2015 in Rambam Health Care Campus, Haifa, Israel. BP was diagnosed as a blistering disease of the skin with the typical established immunopathologic criteria. 4 The diagnosis of psoriasis was based on clinical manifestation with and without histopathologic analysis. The control group consisted of patients who underwent laparoscopic appendectomy and excision of nonmelanoma skin lesions in our institution. Four to 5 control patients were randomly selected for each patient with BP.
Our study consisted of 287 patients newly diagnosed with BP between 2000 and 2015 and 1373 age-, sex-, and ethnicity-matched control subjects. The prevalence rate of psoriasis was greater in patients with BP than in control subjects (5.2% vs 1.2%, respectively; odds ratio, 4.4; 95% confidence interval, 2.2-8.9; P \ .0001). The association was prominent in patients younger than 80 years of age, and its strength was remarkably higher among subjects younger than 60 years. This association was also significant among both sexes and in individuals of Jewish ancestry (Table I) .
Psoriasis preceded the diagnosis of BP in all patients with both diseases, by a mean duration of 25.2 6 18.6 years. Patients with coexisting BP and psoriasis were significantly younger at presentation relative to those with isolated BP (68.5 6 13.7 vs 78.0 6 11.9 years, respectively; P ¼ .003), and the mucosal surfaces were more frequently involved (33.3% vs 15.4%, respectively), with a near-significant difference (P ¼ .077) (Table II) . There was a tendency to treat patients with coexisting BP and psoriasis with adjuvant immunosuppressants more frequently (46.7% vs 20.2%; P ¼ .016) (Table II) .
Psoriasis vulgaris was the most prevalent type of psoriasis (93.3%) in our cohort. Six (40%) of the patients were previously treated with phototherapy and/or climatotherapy for psoriasis, but none of them developed BP during these treatments.
The main limitation of our study was the small sample of patients with coexisting BP and psoriasis.
In conclusion, we report a significant association between BP and psoriasis. Psoriasis preceded BP in all patients having the 2 diseases concomitantly. Relative to those with isolated BP, patients having both diseases were significantly younger. This may be due to the antigenicity of the basement membrane in psoriasis patients being altered at a younger age, stimulating antibasement membrane autoantibody formation and BP development earlier in life. 5 Patients with both entities were treated more frequently with adjuvant immunosuppressants, possibly to avoid high-dose corticosteroids for long durations in psoriatic patients. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
To the Editor: Brodalumab, a human monoclonal antibody that binds to interleukin (IL)-17RA (receptor subunit utilized by pro-inflammatory cytokines IL-17A, IL-17F, and IL-17A/F), has been shown at doses of 210 mg every 2 weeks to be superior to ustekinumab and placebo in treating moderate-to-severe plaque psoriasis in 2 large phase 3 studies: AMAGINE-2 and AMAGINE-3.
1,2
Time to achieve significant improvements in psoriasis disease severity is an important aspect of patient treatment and education. Our objective was to evaluate the speed of action of brodalumab with the use of data from AMAGINE-2 and AMAGINE-3. Detailed study designs are reported elsewhere. 2 In these analyses, efficacy assessments included median times for 25% of patients to achieve Psoriasis Area and Severity Index (PASI) 75, static Physician's Global Assessment (sPGA) success (score 0/1), and median times to achieve 25%, 50%, and 75% reductions in baseline PASI. Estimated times for 25% of patients to achieve PASI 75 were 2.1 (95% confidence interval [CI], 2.0-2.3) weeks for brodalumab and 4.8 (95% CI, 4.5-5.1) weeks for ustekinumab (Fig 1, A) ; times for 25% of patients to achieve sPGA success were 2.5 (95% CI, 2.4-2.6) weeks and 5.6 (95% CI, 5.2-6.0) weeks, respectively (Fig 1, B) . Differences in speed of efficacy between brodalumab and ustekinumab were evident as early as week 1, whereas 3.5% (95% CI, 2.5-4.7) of brodalumab-treated patients achieved sPGA success and PASI 75 in individual independent assessments, compared with 0.7% (sPGA success; 95% CI, 0.2-1.7) and 0.2% (PASI 75; 95% CI, 0.0-0.9) of ustekinumab-treated patients (PASI 75 and sPGA success, both P \.001). By week 12, 85.7% (95% CI, 83.6-87.6) and 79.1% (95% CI, 76.8-81.4) of patients treated with brodalumab achieved PASI 75 and sPGA success, respectively, compared with 69.7% (95% CI, 65.8-73.3) and 59.1% (95% CI, 55.0-63.0) of patients treated with ustekinumab (both P \.001).
Improvement in baseline PASI over time also revealed rapid and sustained brodalumab efficacy. Median time to achieve a 75% improvement in baseline PASI (PASI 75) was estimated at 4.2 weeks for brodalumab and 9.4 weeks for ustekinumab (Fig 2) . Furthermore, times needed to achieve 25% and 50% median improvement in baseline PASI were 0.8 [95% CI, 0.8-0.8] and 1.8 [95% CI, 1.8-1.9] weeks, respectively, for brodalumab compared with 1.8 (95% CI, 1.7-2.0) and 4.5 (95% CI, 4.2-4.8) weeks for ustekinumab (all P \ .0001).
Our data suggest that brodalumab 210 mg every 2 weeks provides rapid improvement in disease severity of moderate-to-severe plaque psoriasis. In addition, comparative data suggest that brodalumab may have the most rapid onset of action of any biologic therapy used in psoriasis (2.1 weeks versus 2.4 weeks for ixekizumab, 3 3.0 weeks for high-dose secukinumab), 4 when using the measure of the time required for 25% of patients to achieve PASI 75. Brodalumab also demonstrates shorter time to achieve a 50% improvement in baseline PASI (1.8 weeks) compared with that reported for ixekizumab (1.9 weeks) 5 or high-dose secukinumab (3 weeks). 4 In addition, the median time to achieve PASI 75 with brodalumab in our study was 4.2 weeks compared with 4.4 weeks, previously reported for ixekizumab. 5 The 
